Diligence memo · auto-generated · as of July 2, 2026

Truepill, Inc.

Truepill, Inc. looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Truepill, Inc. operates in Healthtech, based in Hayward, CA, USA; Remote. API-connected healthcare infrastructure.

Sub-sector tags: Consumer Health Services, healthtech.

Capital & rounds (filed)filed

Truepill, Inc. has raised $307M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $142M on 2021-10-14.

Most recent recorded round closed around 2023-08-16.

Valuation (modeled)modeled

Provath models Truepill, Inc. at approximately $843M (range $353M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.70× the median modeled value of Series D+ Healthtech companies in 2022–2024 (17 peers) — value vs value, same stage and era. Within the normal band (70% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 15 months.

Last raise 2.9 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round was 2.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 99% of Healthtech peers (2138 compared).

Modeled value ranks above 96% of those peers.

Closest niche peers: Monogram Health Holdings, Inc., Lyra Health, Inc., Aledade, Inc., Clarify Health Solutions, Inc., Insightec Ltd.

Peoplefiled

11 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.